当前位置：
X-MOL 学术
›
Lancet Respir. Med.
›
论文详情
Our official English website, www.x-mol.net, welcomes your
feedback! (Note: you will need to create a separate account there.)
COVID-19, ECMO, and lymphopenia: a word of caution.
The Lancet Respiratory Medicine ( IF 38.7 ) Pub Date : 2020-03-13 , DOI: 10.1016/s2213-2600(20)30119-3 Brandon Michael Henry 1
The Lancet Respiratory Medicine ( IF 38.7 ) Pub Date : 2020-03-13 , DOI: 10.1016/s2213-2600(20)30119-3 Brandon Michael Henry 1
Affiliation
|
Extracorporeal membrane oxygenation (ECMO) can serve as life-saving rescue therapy for refractory respiratory failure in the setting of acute respiratory distress syndrome, such as that induced by coronavirus disease 2019 (COVID-19). In the study by Yang and colleagues, who compared clinical characteristics and outcomes in patients with severe COVID-19, five (83%) of six patients receiving ECMO died. Although this sample was small, and specific baseline characteristics and disease courses were almost unknown, it raises concerns about potential harms of ECMO therapy for COVID-19.
中文翻译：
COVID-19，ECMO和淋巴细胞减少症：警告。
体外膜氧合（ECMO）可以作为急性呼吸窘迫综合征（例如由冠状病毒病2019（COVID-19）诱发的急性呼吸窘迫综合征）中的挽救生命的抢救疗法。在Yang和同事的研究中，他们比较了严重COVID-19患者的临床特征和结局，在接受ECMO的6例患者中有5例（83％）死亡。尽管该样本很小，并且几乎不知道具体的基线特征和疾病进程，但它引起了人们对ECMO治疗COVID-19的潜在危害的担忧。
更新日期：2020-04-03
中文翻译：
COVID-19，ECMO和淋巴细胞减少症：警告。
体外膜氧合（ECMO）可以作为急性呼吸窘迫综合征（例如由冠状病毒病2019（COVID-19）诱发的急性呼吸窘迫综合征）中的挽救生命的抢救疗法。在Yang和同事的研究中，他们比较了严重COVID-19患者的临床特征和结局，在接受ECMO的6例患者中有5例（83％）死亡。尽管该样本很小，并且几乎不知道具体的基线特征和疾病进程，但它引起了人们对ECMO治疗COVID-19的潜在危害的担忧。
京公网安备 11010802027423号